William Blair analyst Andy Hsieh has maintained their bullish stance on CRBP stock, giving a Buy rating on October 7.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Andy Hsieh has given his Buy rating due to a combination of factors that suggest a favorable risk/reward profile for Corbus Pharmaceuticals. The upcoming data readout from the Phase I/II trial of CRB-701, an antibody-drug conjugate targeting nectin-4, is anticipated to provide significant insights into its efficacy in treating bladder, cervical, and head and neck cancers.
The trial results, which will be presented at the European Society for Medical Oncology annual meeting, are expected to reveal objective response rates that could generate substantial investor interest, particularly if they meet or exceed the thresholds of 30% for cervical cancer and 40% for head and neck cancer. The anticipation of positive outcomes from these trials underpins the optimistic outlook, making the stock an attractive buy opportunity.
In another report released on October 7, Mizuho Securities also reiterated a Buy rating on the stock with a $32.00 price target.